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Abstract
Introduction
Antipsychotic (AP) safety has been widely investigated. However, mechanisms underlying
AP-associated pneumonia are not well-defined.
Aim
The aim of this study was to investigate the known mechanisms of AP-associated pneumo-
nia through a systematic literature review, confirm these mechanisms using an independent
data source on drug targets and attempt to identify novel AP drug targets potentially linked
to pneumonia.
Methods
A search was conducted in Medline and Web of Science to identify studies exploring the
association between pneumonia and antipsychotic use, from which information on hypothe-
sized mechanism of action was extracted. All studies had to be in English and had to con-
cern AP use as an intervention in persons of any age and for any indication, provided that
the outcome was pneumonia. Information on the study design, population, exposure, out-
come, risk estimate and mechanism of action was tabulated. Public repositories of pharma-
cology and drug safety data were used to identify the receptor binding profile and AP safety
events. Cytoscape was then used to map biological pathways that could link AP targets and
off-targets to pneumonia.
Results
The literature search yielded 200 articles; 41 were included in the review. Thirty studies
reported a hypothesized mechanism of action, most commonly activation/inhibition of
PLOS ONE | https://doi.org/10.1371/journal.pone.0187034 October 27, 2017 1 / 22
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Sultana J, Calabro´ M, Garcia-Serna R,
Ferrajolo C, Crisafulli C, Mestres J, et al. (2017)
Biological substantiation of antipsychotic-
associated pneumonia: Systematic literature review
and computational analyses. PLoS ONE 12(10):
e0187034. https://doi.org/10.1371/journal.
pone.0187034
Editor: Kenji Hashimoto, Chiba Daigaku, JAPAN
Received: May 31, 2017
Accepted: October 12, 2017
Published: October 27, 2017
Copyright: © 2017 Sultana et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All the
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analyses the following free and publicly available
database was used: ChEMBL (http://www.ebi.ac.
uk/chembl/). For Cytoscape analyses the following
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available online: Gene Ontology Consortium
databases (GO databases) http://www.
geneontology.org/, Kyoto Encyclopedia of Genes
and Genomes, also known as KEGG (http://www.
genome.jp/kegg/), Reactome Pathway Database
cholinergic, histaminergic and dopaminergic receptors. In vitro pharmacology data con-
firmed receptor affinities identified in the literature review. Two targets, thromboxane A2
receptor (TBXA2R) and platelet activating factor receptor (PTAFR) were found to be novel
AP target receptors potentially associated with pneumonia. Biological pathways constructed
using Cytoscape identified plausible biological links potentially leading to pneumonia down-
stream of TBXA2R and PTAFR.
Conclusion
Innovative approaches for biological substantiation of drug-adverse event associations may
strengthen evidence on drug safety profiles and help to tailor pharmacological therapies to
patient risk factors.
Introduction
Antipsychotics drugs (APs) have been associated with several adverse reactions including
stroke, acute kidney disease and pneumonia, especially in aged patients [1–3]. In 2009 the
Food and Drug Administration issued a warning on the increased risk of death when APs
were used off-label in persons with dementia, pneumonia being among the most commonly
reported causes of death. Many observational studies have evaluated the association between
APs and the risk of community or hospital-acquired pneumonia in the elderly population [4–
14]. However, most studies investigated APs by class rather than by individual drug, with a few
exceptions. In this respect, classifying drugs as conventional or atypical is a traditional perspec-
tive still reminiscent of the one drug–one target paradigm [15]. It is now widely recognized
that most drugs bind with different affinities to multiple proteins, including but not limited to
traditional receptor targets [16], a property often referred to as polypharmacology [17].This
makes each single drug essentially unique pharmacologically.
The biological pathways underlying antipsychotic-induced pneumonia are not currently
known, although several plausible hypotheses have been postulated [18]. Understanding
which drugs are associated with the highest risk of pneumonia would allow prescribers to
select drugs with a lower risk of pneumonia in persons with risk factors predisposing them to
infectious respiratory diseases. Such risk factors include being bedridden, having chronic
respiratory diseases and/or being prescribed sedating drugs. There is emerging data from
observational studies suggesting a different safety profile for individual APs, which may be
missed when studying drug effects by class [19, 20]. The potential effects of such differences in
adverse drug reactions (ADRs) among single APs could in turn have an impact on AP persis-
tence and healthcare utilization as a result of ADRs, or relapse of symptoms because of differ-
ential AP drug discontinuation. While observational studies are a crucial starting point for the
identification of increased risk of adverse drug reactions they cannot point to an underlying
biological mechanism. Nevertheless, identifying a biologically plausible cause for drug-related
risk, i.e. signal substantiation, is essential to confirm the validity of such risk and identify new
off-targets that otherwise cannot be predicted on the basis of ‘traditional’ systems pharmacol-
ogy, i.e. cholinergic, histaminergic, or serotonergic systems etc. Signal substantiation is defined
as any activity aiming to provide a biological explanation of why an ADR occurs[21]. The
rationale behind this is that an ADR must be biologically plausible to increase the feasibility of
Biological substantiation: Antipsychotics and pneumonia
PLOS ONE | https://doi.org/10.1371/journal.pone.0187034 October 27, 2017 2 / 22
(http://reactome.org/), Pathway Common (http://
www.pathwaycommons.org/pc/dbSources.do),
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further identify pharmacological data. All the data
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(as indicated on main text). Finally, the Pubmed
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was used to manually integrate recently published
related data.
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a causal relationship between drug and ADR, in particular for type A ADRs, i.e. those which
are dose-dependent and are related to the drug’s known pharmacological activity.
The aims of this study were to: 1) conduct a systematic review aiming to identify all
hypothesized mechanisms of AP-associated pneumonia in published literature, including
studies employing any study designs (including case reports), in which persons of any age
used APs for any indication, provided that the outcome was pneumonia; 2) confirm the
most relevant drug targets potentially involved in AP-associated pneumonia using compu-
tational approaches for drug safety profiling [22], as well as to identify novel drug targets,
with the ultimate goal of extrapolating clinically relevant information.
Methods and materials
Literature review
Medline and Web of Science were searched for literature from their inception to 27th February
2017 using the following terms: “pneumonia” and “antipsychotic agents”. Articles were
excluded if they were not published in English language or if the full text of the article was not
accessible even after contacting the author. Eligibility criteria included treatment with APs for
any indication in persons of any age and pneumonia as the outcome under investigation. All
study designs and article types were eligible for inclusion, including case reports, letters to the
editor, observational studies and systematic reviews/meta-analyses. For observational studies
reporting a risk of pneumonia with AP use, the study design, population studied, exposure
and comparator, outcome investigated, hypothesized mechanism underlying AP-associated
pneumonia and risk estimate was reported. Two investigators independently examined the
titles and abstracts of selected articles and obtained full texts of potentially relevant papers. Dis-
agreement on inclusion was resolved by discussion. The findings were reporting accordingly
the PRIMA checklist (S1 Fig).
Screening of known and predicted antipsychotic binding to receptors and
associated safety events
CT-link software [22] was used to analyze the experimentally known pharmacology and its
potential link to known safety outcomes of AP drugs. Known in vitro pharmacology data was
extracted from ChEMBL [23]. Statistically significant protein signatures associated to each
safety outcome were generated by analyzing the confusion matrix resulting from the number
of drugs with affinity above or below a certain affinity threshold for a given target and associ-
ated, or otherwise, to a given safety event. Protein signatures were defined for 1,455 safety
terms, mapped to Unified Medical Language System (UMLS) codes, and classified in 25 toxic-
ity categories [24]. CT-link was screened for targets and safety outcomes associated with a set
of 7 APs commonly investigated in the relation to the risk of pneumonia, namely, amisulpride,
clozapine, haloperidol, olanzapine, quetiapine, risperidone, and zotepine [25–29].
Pathway construction
Once targets of interest were identified in CT-Link (i.e., novel targets), the pathways that could
potentially explain a novel biological link between AP off-targets, i.e., binding targets other
than intended ones, and safety terms related to pneumonia were identified and investigated
using the following software: Cytoscape [30], the GeneMania [31], ClueGO [32] and CyTarget
Linker [33] plug-ins (S3 Fig). Cytoscape software was used to find group of elements, either
genes or proteins, that interact with the user-defined query (which consists of one or more
genes/proteins), representing them graphically. Each of the elements (either genes or proteins)
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found by Cytoscape are referred as “nodes” (graphically represented by circles). The interac-
tions are referred as edges (graphically represented by lines connecting different nodes).
To construct a possible molecular pathway downstream of antipsychotic binding to its off-
targets, two approaches were used. In the first approach, a “Physical Interactions” database
was used [31] to identify possible proteins and/or metabolic products that may be responsive
to the function of the identified proteins to which AP drugs bind. Cytoscape was used to iden-
tify all known nodes which physically interact with AP off-targets, using data inputs from the
“Physical Interactions” database of geneMania plug-in. This step was iterated, using the results
of the previous step as input, to widen the biological net of physical interactors.
In the second approach, the “Pathway Commons” [31] database was used in order to iden-
tify nodes related to the function of the off-targets identified. For this step, Cytoscape was fur-
ther screened to identify the pathways that are functionally linked with AP protein targets and
pneumonia-related symptoms. The “Pathway Commons” database of the geneMania plug-in
was used in this step. All molecular cascades, including those weakly related to our starting
query, were identified. Nodes not related to the phenotype under investigation were removed
manually.
Selection and clustering of candidate genes from the biological net
identified: Mapping of hypothetical molecular cascades leading to AP-
derived pneumonia due to novel targets
The relevance of the interactors to pneumonia-related symptoms was checked through the use
of Medline and Cytoscape built-in databases. The nodes having a stronger association were
highlighted. These are hereafter referred to as associated nodes(AN). Nodes within the biologi-
cal net, linking the associated nodes to identified AP off-targets were clustered, where a cluster
is defined as a subgroup of nodes within the biological net under investigation that share a par-
ticular characteristic. In this case, the common characteristic is that they are related to both AP
targets and the associated nodes found in the biological net. ClueGo [32] and CluePedia [34]
plug-ins were then used to identify pathways involved in the function of the nodes included in
the clusters.
Results
Literature review
The results of the article selection process are reported in Fig 1. The search in Medline and
Web of Science yielded 200 articles. Of these, only 48 articles were deemed suitable for further
consideration as they specifically concerned APs as drugs of interest which may have led to
pneumonia. Seven articles were subsequently excluded because they were not in English or
had no full text available, even after the authors were contacted (see S1 Table for details on
excluded studies with no full text). Forty-one articles were included in the final assessment and
of these, the majority were observational studies (N = 16) [1, 4, 6–10, 12, 13, 18, 25–29, 35–46].
Of the 41 articles included, 30 hypothesized a mechanism of action. Ten studies were reviews/
meta-analyses [1, 13, 18, 27, 41–46], while other studies included 12 case reports [47–58]and
one letter to the editor[15]. Most of the literature concerned patients aged 65 and older [1, 4, 6,
8–10, 12, 18, 35, 38, 41, 45, 47, 49, 51] while others investigated an adult population with bipo-
lar/schizophrenic disorders [26, 36, 37, 40, 48, 50, 55, 56, 59]. No randomized clinical trials
(RCTs) were identified, but one meta-analysis of 6 RTCs was found [27](S2 Fig). Limited
information on the effect of dose and duration regarding the risk of pneumonia was available,
although some studies suggested an increased risk of pneumonia with higher AP doses [4, 29]
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Fig 1. Selection of publications in Medline and Web of Science, using the PRISMA model.
https://doi.org/10.1371/journal.pone.0187034.g001
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and mostly close to the start of treatment [29], while another study found no clear link between
the duration of AP exposure and risk of pneumonia[39]. Some groups of AP-treated persons
were found to be at higher risk of pneumonia, including persons with Parkinson’s disease [25],
schizophrenia [25], and those concomitantly using multiple antipsychotic drugs [26].
The most widespread theories about the biological mechanisms underlying pneumonia due
to antipsychotic use concern the affinity of the antipsychotics to cholinergic [1, 4, 6, 8, 9, 12,
18, 25, 26, 36, 37, 43, 45, 48, 51, 59], histaminergic [4, 6, 9, 25, 26, 43–45, 59] and dopaminergic
[1, 6, 9, 18, 25, 36, 41–44, 49, 58]receptors (Table 1). The clinical events triggered by APs bind-
ing to their targets and leading to pneumonia are summarized in Table 1.These include dry
mouth and impaired peristalsis due to muscarinic M1 receptor blockade, as well as sedation
with subsequent impaired swallowing due to histamine H1 receptor blockade. Lesser known
mechanisms proposed involved the immune system [6, 10, 26, 36, 41, 43], cytochrome metab-
olism system [47], inflammatory pathways [15, 41], an eotaxin (i.e., a chemoattractant for
eosinophils) and serotonin eosinophilic-specific chemo-attracting action leading to eosino-
philic pneumonia [49].
Most of the hypotheses concerned antipsychotic drug classes rather than individual drugs,
or referred to antipsychotics in general. Several studies did not specify a biological mechanism
leading to pneumonia but described the antipsychotic-associated clinical signs or symptoms
which may cause pneumonia [10, 15, 35, 42, 44, 50, 53, 54]. The most commonly hypothesized
physiological/clinical conditions leading to antipsychotic-associated pneumonia were extrapy-
ramidal symptoms (5 studies reporting extrapyramidal symptoms with conventional APs, 5
studies where AP class was not specified; none for atypical APs), sedation (7 studies reporting
sedation with conventional APs, 5 with atypical APs, 6 where class was not specified), xerosto-
mia (6 studies reporting xerostomia after atypical AP use, 2 studies not specifying AP drug
class and none for conventional APs) and oropharyngeal dyskinesia/impaired swallowing (10
studies reporting this for atypical APs, 8 without specifying a drug class; none for conventional
APs). Less common clinical features included aspiration, sialorrhea, agranulocytosis, and sup-
pression of the cough reflex.
Of all the observational studies/reviews identified, 17 reported a risk estimate of pneumonia
associated with antipsychotic use (Table 2). Most risk estimates were available for AP drug
classes rather than individual drugs, suggesting that the overall risk of pneumonia associated
with atypical APs is similar to conventional APs, when non-use of APs was the reference
group. No comparison of pneumonia risk could be made for individual APs due to the variety
of reference groups used.
Off-target pharmacology and links to respiratory safety events
The results of the search in CT-link for the known AP receptor-binding profile broadly con-
firmed the results of the literature review (Fig 2). The comparison of the experimental affinity
profiles of the 7 APs across a set of proteins for which in vitro affinity data was available shows
that, even though these drugs are all considered to belong to the same pharmacological class,
there are significant differences between their pharmacologic profiles. For example, amisul-
pride and haloperidol show a clear binding preference for the dopamine receptors D2 (DRD2)
and D3 (DRD3), while having a much weaker affinity for the histamine H1 receptor (HRH1)
than the other APs. In addition, with the exception of quetiapine and amisulpride, all APs bind
strongly to the serotonin receptor subtypes 5-HT2A (HTR2A) and 5-HT2C (HTR2C). Also, in
general, clozapine and risperidone seem to interact more strongly with the alpha-2A adrenergic
receptors than the other APs. Finally, olanzapine and clozapine interact markedly with the mus-
carinic receptors compared to other APs. Altogether, the unique polypharmacology of every
Biological substantiation: Antipsychotics and pneumonia
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Table 1. Summary of potential biological mechanisms underlying antipsychotic-associated pneumonia identified in the literature.
Receptor system Molecular/cellular target Associated signs/symptoms Antipsychotic drug or drug
class
Cholinergic
system
M2, M3 and M5 receptor antagonism [59] - Clozapine
M4 muscarinic receptor agonism[48, 59] Hypersalivation[37, 59] Clozapine
M1 muscarinic receptor antagonism
[26, 59]
Xerostomia[26, 36, 37] Clozapine
Xerostomia[36] Olanzapine
Esophageal dilatation and
hypomotility[26, 36, 37]
Clozapine
Esophageal dilatation and
hypomotility[36]
Olanzapine
Impaired peristalsis[36] Olanzapine
Impaired peristalsis
[36, 37]
Clozapine
Interaction with muscarinic receptor system with no specification as to receptor
subtype and nature of effect (agonist or antagonist)
[1, 9, 12, 18, 43]
Not specified Not specified
Anticholinergic activity with no specification to receptor subtype [8, 25] Xerostomia[4, 6, 43, 45] Atypical APs
Anticholinergic activity with no specification to receptor subtype [45] Aspiration[4, 8, 45] Conventional APs
Anticholinergic activity with no specification to receptor subtype[4] Esophageal dysfunction [8] Atypical APs
Decreased peristaltic function[8] Not specified
Bronchorrhea[51]
Hypersalivation[51]
Hypersalivation
[37]
Clozapine
Adrenergic system Alpha-2 receptor antagonism
[48]
Not specified Clozapine
Serotonergic
system
5-HT2a receptors antagonism
[49]
Not specified Risperidone
Dopaminergic
system
Post-synaptic D2 receptors antagonism [49] Not specified Risperidone
D2 receptors[36] Extrapyramidal symptoms[36] Haloperidol
Dopaminergic activity with no specification to receptor subtype and nature of effect
(agonist or antagonist)[9, 25, 43]
Extrapyramidal symptoms[4, 9, 25,
45]
Conventional APs
Dopaminergic activity with no specification to receptor subtype and nature of effect
(agonist or antagonist)[1, 41–44]
Extrapyramidal symptoms
[30–33]
Not specified
Dysphagia[29, 43] Not specified
Oropharyngeal dyskinesia[6, 43]
Oropharyngeal rigidity and spasm[6,
43]
Aspiration[6, 58]
Gasping and choking[58]
Histaminergic
system
H1 receptor blockade[45] Sedation
[4, 6, 9, 25, 26, 43–46]
Conventional APs
H1 receptor blockade [6, 25, 43, 44, 46] Impaired swallowing
[4, 6, 9, 25, 43, 45]
Atypical APs
H1 receptor blockade[26] Aspiration[4, 37, 43, 45] Clozapine, olanzapine, and
quetiapine
H1 receptor blockade [43, 44] Not specified Phenothiazines
Not specified Not specified
H1 receptor blockade[59] Impaired esophageal peristalsis, due
to sedation [59]
Clozapine
Effect on H1 receptors, with no specification as to nature of effect (agonist or
antagonist)
Sedation[29] Not specified
No subtypes specified Sedation[29, 36, 37] Olanzapine, clozapine
- Immune system[29] Agranulocytosis[10] Not specified
Altered cytokine profile [41] Individual APs or class not
specified
Agranulocytosis[6, 26, 43, 59] Clozapine
(Continued)
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individual antipsychotic will ultimately translate in a unique drug safety profile associated with
those protein interactions.
Most drugs are the result of a long and careful drug design process aiming at maximizing
the affinity of a drug for its primary intended target, in the case of antipsychotics, dopaminer-
gic receptor blockade. The primary targets of a drug are therefore those proteins for which the
drug has strongest affinity. Accordingly, a total of 41 protein interactions with binding affinity
stronger than 10nM (pKi 8.0) are currently experimentally known for those 7 APs [23]. Of
these, 39 interactions (95%) are with aminergic G protein-coupled receptors. They will be
most likely the main factor responsible for some of the antipsychotic-associated pneumonias
reported. However, in spite of the optimization process, most drugs will still have residual,
weaker, affinities for other proteins. In the case of the 7 APs in this study, the number of
known protein interactions goes up to 184 when considering weaker binding affinities, such as
1μM (pKi 6.0). This off-target pharmacology, i.e. drugs targets other than the known and/or
expected ones, could also contribute and be partly responsible for some of the respiratory
safety events linked to pneumonia. The identified off-targets as potentially novel mediators of
AP-associated pneumonia were then screened using a repository of drugs and their associated
safety events. The thromboxane A2 receptor (TBXA2R) and the platelet-activating factor
receptor (PTAFR) were preliminarily identified as such novel off-targets of interest for which
micromolar affinity was observed for all 7 APs except for amisulpride.
A repository of the data from drug labels, safety predictions and ontologies in CT-link was
used to screen safety events associated with the set of 7 APs. It was found that a total of 95
respiratory safety terms were associated with these antipsychotics. The most commonly identi-
fied terms were alveolitis, lung diseases, dyspnea, and respiration disorders (S2 Table). The
antipsychotics most consistently linked to pneumonia-related signals were quetiapine and ris-
peridone, whereas the least associated with pneumonia-related signals were olanzapine and
clozapine. Interestingly, the latter were the two antipsychotics having a receptor binding
Table 1. (Continued)
Receptor system Molecular/cellular target Associated signs/symptoms Antipsychotic drug or drug
class
- No pharmacologic or other systems specified Sedation[1, 10, 41–43] Not specified
Sedation[48] Clozapine
Sedation[8] Atypical APs
Impaired swallowing and dysphagia
[10, 41–43, 54]
Not specified
Impaired swallowing and dysphagia
[28]
Atypical APs
Impaired swallowing and dysphagia
[15, 48]
Clozapine
Xerostomia[10, 42] Not specified
Hypersalivation[15, 48, 50] Clozapine
Esophageal dysfunction [15, 50] Clozapine
Suppression of cough reflex [41, 54] Not specified
Sialorrhea
[53]
Clozapine
Hypertonic movement of pharyngeal
muscles
[54]
Not specified
Abbreviations- AP: antipsychotic.
https://doi.org/10.1371/journal.pone.0187034.t001
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Table 2. Summary of all identified observational studies investigating the risk of antipsychotic-associated pneumonia.
Type of study Study population Exposure Mechanisms hypothesized Outcome and risk estimate
(95% CI)
High risk groups
Nested case-control
study[25]
Persons aged65 Olanzapine, risperidone,
quetiapine, ziprasidone,
aripiprazole
The increased risk of pneumonia with olanzapine
compared to quetiapine could be due to the increased
affinity of olanzapine to histaminergic and muscarinic
receptors compared to quetiapine.
Pneumonia may be mediated via extrapyramidal effects,
sedation, impaired swallowing.
Pneumonia risk (quetiapine
as comparator)
Risperidone HRAdj = 1.14
(1.10–1.18)
Olanzapine HRAdj = 1.10
(1.04–1.16)
Ziprasidone HRAdj = 0.97
(0.81–1.16)
Aripiprazole HRAdj = 0.92
(0.84–1.00)
Parkinson’s disease
Systematic review and
meta-synthesis of
observational studies [41]
Persons aged65 Conventional or atypical
APs
The risk of pneumonia among conventional APs may be
mediated by extrapyramidal effects, leading to pharyngeal
rigidity and dysphagia, and sedation, in turn leading to
suppression of the cough reflex and a higher risk of
aspiration.
APs may also modulate cytokine levels and immune
response but it is not clear how this may differ between
conventional and atypical agents.
Average pneumonia
relative risk and range
(atypical APs as comparator)
RR = 1.01 (0.84–1.28)
None specified
Retrospective cohort
study[9]
Long-term care
residents aged65
Conventional or atypical
APs
Conventional APs may cause dysphagia. Their affinity to
dopaminergic receptors causes extrapyramidal adverse
effects that can lead to pneumonia. Both atypical and
conventional APs may have significant anticholinergic
effects which increase the risk of pneumonia.
Histamine H1 receptor blockade may lead to sedation,
which may be associated with dysphagia and possibly,
aspiration pneumonia.
Risk of pneumonia
(atypical APs as comparator)
HR = 1.24(0.94–1.64)
None specified
Nested case-control
study[6]
Persons aged65 Any AP or APs by class Pneumonia may be due to aspiration, dysphagia and/or
impaired cough reflex.
Dopaminergic blockade may lead to dyskinesia of the oro-
pharyngeal muscles, rigidity and spasm of the pharyngeal
muscles which increases the risk of aspiration.
The blocking of dopamine receptors may also result in
hyperfunctional involuntary movements (dyskinesia) of the
oral pharyngeal musculature, rigidity, and spasm of the
pharyngeal musculature, which can result in aspiration.
Another mechanism involves dryness of the mouth that
leads to impaired oropharyngeal bolus transport.
Furthermore, sedation is also a well-known cause of
swallowing problems, in particular caused by histamine-
1-receptor blocking in the central nervous system. Some
APs are known to have direct or indirect effects on the
immune system. In less than 1% of treated patients
clozapine may cause agranulocytosis, which increases the
risk of infections.
Risk of pneumonia with any
AP use(non-use as
comparator)
Current use (0 to 7 days)
ORAdj = 1.6 (1.3–2.1)
Recent past use (8–30 days)
ORAdj = 0.89 (0.5–1.6)
Past use (>31 days) ORAdj =
0.69 (0.5–1.0)
Risk of pneumonia by AP
class
(non-use as comparator)
Use of atypical APs ORAdj =
3.1 (1.9–5.1)
Use of conventional APs
ORAdj = 1.5 (1.2–1.9)
Use of both classes ORAdj =
1.9 (0.5–7.4)
None specified
Nested case-control
study[26]
Persons with a
schizophrenia
diagnosis
Conventional APs by
class; atypical APs by
class and individually
Pneumonia may occur due to AP drugs binding to
histaminergic-1 (H1) receptors and muscarinic-1 (M1)
receptors. Atypical APs with a strong binding affinity for
histaminergic-1 (H1) receptors or with significant
cholinergic activity may increase the risk of pneumonia.
Risk of hospitalization for
pneumonia by drug class and
for individual class (non-use
as comparator)
RRAdj for any current use of
atypical APs = 1.69 (1.43–
2.01)
RRAdj for current clozapine
use = 3.18 (2.62–3.86)
RRAdjfor current olanzapine
use = 1.83 (1.48–2.28)
RRAdj for current quetiapine
use = 1.63 (1.31–2.04)
RRAdj for current zotepine
use = 1.48 (1.15–1.91)
RRAdj for current risperidone
use = 1.32 (1.12–1.56)
RRAdj for current amisulpride
use = 1.14 (0.79–1.65)
RRAdj for any current use of
conventional APs = 1.38
(0.92–2.07)
Persons prescribed clozapine
concomitantly with olanzapine,
quetiapine, risperidone,
quetiapine, zotepine or
amisulpride; persons
prescribed clozapine,
risperidone, quetiapine,
olanzapine or zotepine
concomitantly with other non-
clozapine APs
Systematic review and
meta-analysis[44]
Persons of all ages Any AP drug; meta-
analysis conducted for
conventional
antipsychotics or atypical
antipsychotics compared
to non-use
Extrapyramidal effect may mediate aspiration pneumonia. Risk of pneumonia
(non use as comparator)
OR for conventional AP
use = 1.68 (1.39–2.04)
OR for atypical AP use = 1.98
(1.67–2.35)
Chronic obstructive pulmonary
disease, asthma, diabetes
mellitus, congestive heart
failure, smoking, malnutrition
(Continued)
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Table 2. (Continued)
Type of study Study population Exposure Mechanisms hypothesized Outcome and risk estimate
(95% CI)
High risk groups
Case control study[8] Hospitalized
persons aged65
Atypical
APs (clozapine,
olanzapine, quetiapine,
aripiprazole, ziprasidone,
and risperidone)
AP -associated esophageal dysfunction can cause
pneumonia. Sedation due to anticholinergic effects
decreases peristaltic function increasing the risk of
aspiration.
Risk of community acquired
pneumonia
(use of atypical APs in
persons who did not develop
pneumonia as comparator)
ORAdj = 2.26 (1.23–4.15)
Chronic obstructive
pulmonary disease, asthma,
diabetes
mellitus, congestive heart
failure, smoking
Nested case-control[4] Persons65 years Atypical or conventional
AP use
Conventional APs may lead to extrapyramidal effects as
akinesia which increase the risk of aspiration. Pneumonia
may also be due to anticholinergic receptor blockade that
causes xerostomia and impaired peristalsis and
H1-receptor blockade that causes sedation.
Risk of fatal or non-fatal
pneumonia (past use as
comparator)
ORAdjfor current atypical
antipsychotic use = 2.61
(1.48–4.61)
ORAdj for current
conventional antipsychotic
use = 1.76 (1.22–2.53)
ORAdj for current
butyrophenone use = 1.57
(1.06–2.30)
ORAdj for current
phenothiazine use = 4.16
(1.46–11.87)
ORAdjforcurrent use of other
conventional
antipsychotics = 2.26 (1.21–
4.24)
ORAdjfor current risperidone
use = 3.51 (1.94–6.36)
ORAdjfor current olanzapine
use = 1.90 (0.61–5.90)
ORAdjfor current of
piamperidone = 1.55 (1.00–
2.43)
ORAdjfor current use of
haloperidol = 1.95 (1.20–
3.17)
ORAdjfor current use of
zuclopenthixol = 2.25 (1.00–
5.08)
Use of0.15 defined daily
dose for both drug classes
Retrospective cohort
study[38]
Persons with
dementia aged65
Conventional or atypical
APs
None specified Risk of pneumonia for
conventional APs (atypical
APs as comparator)
ORAdj = 1.57 (1.05–2.34)
None specified
Retrospective cohort
study[12]
Nursing home
residents aged
65years
Psychotropic drugs:
antidepressants, atypical
APs, benzodiazepines,
conventional APs.
Anticholinergic effects may give rise to pneumonia Risk of pneumonia with
conventional APs (atypical
APs as comparator)
RRAdj = 0.94 (0.56–1.58)
None specified
Meta-analysis of 6
double-blind phase II and
III trials investigating the
use of risperidone in
Alzheimer’s disease
patients compared to
placebo[27]
Alzheimer’s
disease patients
Risperidone None specified Risk of pneumonia as cause
of death with risperidone
compared to placebo
% deaths = 1.0 (0.38–1.60)
None specified
Retrospective cohort
study[7]
Elderly persons
admitted to hospital
for pneumonia
Conventional or atypical
APs
None specified Risk of in-hospital death for
pneumonia patients (i.e. fatal
pneumonia)
(non-use as comparator)
Conventional AP ORAdj =
1.51 (1.04–2.19)
Atypical AP ORAdj = 1.20
(0.96–1.50)
None specified
(Continued)
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Table 2. (Continued)
Type of study Study population Exposure Mechanisms hypothesized Outcome and risk estimate
(95% CI)
High risk groups
Retrospective cohort
study[36]
Persons with a
diagnosis of bipolar
disease
Conventional or atypical
APs or single individual
APs
Olanzapine and clozapine may cause pneumonia through
an anticholinergic effect at M1 receptors, inducing dry
mouth, esophageal dysfunction and impaired peristalsis.
Both these drugs may also cause sedation through an
antihistaminergic effect. Haloperidol may increase the risk
of pneumonia through extrapyramidal symptoms mediated
by dopamine-2 receptors.
Risk of pneumonia
(non-current use as
comparator)
RRAdj for any atypical AP
= 2.07(1.58–2.71)
RRAdj for clozapine = 2.59
(1.90–4.66)
RRAdj for olanzapine = 2.97
(1.90–4.66)
RRAdj for quetiapine = 2.12
(1.48–3.03)
RRAdj for zotepine = 1.52
(0.98–2.38)
RRAdj for risperidone = 1.74
(1.21–2.50)
RRAdj for conventional
AP = 2.32 (1.76–3.05)
RRAdj for
chlorpromazine = 1.10 (0.68–
1.78)
RRAdj for haloperidol = 3.68
(2.66–5.09)
RRAdj for sulpiride = 1.29
(0.94–1.76)
None specified
Retrospective cohort
study[37]
Persons with a
diagnosis of
schizophrenia
Conventional or atypical
APs or single individual
APs
Clozapine may cause pneumonia through an M1 receptors
blockade, inducing dry mouth, esophageal and impaired
peristalsis; clozapine may paradoxically also cause
excessive salivation due to disrupted cholinergic function
which increases the risk of pneumonia
Risk of pneumonia
(non-current use of APs, i.e.
use > 30 days of the date of
pneumonia)
RRAdj for conventional
APs = 0.97 (0.75–1.25)
RRAdj for
chlorpromazine = 0.83 (0.48–
1.44)
RRAdj for haloperidol = 1.11
(0.80–1.52)
RRAdj for flupenthixol = 0.88
(0.43–1.44)
RRAdj for sulpiride = 0.96
(0.70–1.33)
RRAdj for atypical APs = 0.92
(0.72–1.18)
RRAdj for clozapine = 1.40
(1.05–1.88)
RRAdj for olanzapine = 1.09
(0.71–1.67)
RRAdj for quetiapine = 1.08
(0.73–1.59)
RRAdj for zotepine = 0.79
(0.46–1.37)
RRAdj for risperidone = 0.62
(0.46–0.84)
RRAdj for amisulpride = 1.11
(0.61–2.01)
RRAdj for aripiprazole = 0.71
(0.33–1.54)
Cancer, cardiovascular
disease, asthma, anti-
inflammatory medications
Self-controlled case
series[39]
Elderly persons
with pneumonia
Conventional or atypical
APs
None specified Risk of pneumonia within the
first week after AP initiation
(non-exposure as
comparator)
RRAdj for conventional
APs = 2.07 (1.45–2.95)
RRAdj for atypical APs = 1.92
(1.44–2.56)
None specified
(Continued)
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profile markedly different from the other APs in their preferred binding for muscarinic recep-
tors (Fig 2).
Among the off-targets identified, further analysis was carried out for the two potentially
novel proteins involved in AP-associated pneumonia, TBXA2R and PTAFR. Drug safety
events (including respiratory events) in CT-link are linked to data on the receptors potentially
associated with that safety event. Pneumonia in relation to the antipsychotics screened was
indeed found to be associated with TBXA2R and PTAFR.
Biological pathway construction
Findings on the potential role of TBXA2R and PTAFR in the increased risk of antipsychotic-
associated pneumonia derived from CT-link were further investigated using Cytoscape. Sev-
eral candidate genes encoding for proteins that physically interact with TBXA2R and PTAFR
were identified. The pathways involved in the function of the clustered genes are shown in
Figs 3 and 4. The identified AP off-targets, TBXA2R and PTAFR, in black, are linked, either
directly or indirectly, to a group of nodes, shown in blue, which likely contribute to the
increased risk of developing pneumonia-related symptoms after activation of TBXA2Ror
PTAFR. The molecular cascade highlighted in these analyses is involved in a wide range of bio-
logical functions. The biological processes (identified from the Gene Ontology Database -
http://geneontology.org/) related to the molecular cascade for both TBXA2R and PTAFR are
indicated in Fig 5, while S3 and S4 Tables report the details of biological processes and sub-
processes indicated in Fig 5. As shown by the supplementary files (S3–S6 Figs), several path-
ways were influenced by the function of the clustered nodes. While some of these clusters
point to biological functions which seem completely unrelated to pneumonia-related
Table 2. (Continued)
Type of study Study population Exposure Mechanisms hypothesized Outcome and risk estimate
(95% CI)
High risk groups
Retrospective cohort
study [28]
Elderly persons
who underwent a
coronary artery by-
pass graft
Conventional or atypical
APs; olanzapine,
quetiapine or risperidone
vs. haloperidol in
sensitivity analysis
Atypical APs can cause aspiration pneumonia by impairing
swallowing.
Risk of pneumonia after
cardiac surgery (conventional
AP as comparator)
RR for atypical APs after
propensity score
matching = 1.11 (0.89–1.38)
Risk of pneumonia after
cardiac surgery (haloperidol
as comparator)
RR for quetiapine after
propensity score
matching = 0.99 (0.76–1.29)
RR for risperidone after
propensity score
matching = 1.19 (0.91–1.56)
RR for olanzapine after
propensity score
matching = 1.11 (0.83–1.47)
None specified
Retrospective cohort
study [29]
Persons with
Alzheimer’s
disease and
persons with no
Alzheimer’s
disease
Any AP use; risperidone,
quetiapine and haloperidol
AP drugs can cause pneumonia as a result of
extrapyramidaleffects, swallowing impairment, and
sedation, caused by action on the dopaminergic,
cholinergic, and histaminergic systems.
Otherpossiblemechanismsmayoccurthrough the immune
system.
In persons with AD,
risk of pneumonia (non-use
as comparator)
HRAdj for any AP use = 3.43
(2.99–3.93)
HRAdj for quetiapine
(risperidone as comparator)
= 0.77 (0.58–1.03)
HRAdj for haloperidol
(risperidone as comparator)
= 1.90 (1.25–2.90)
Increasing dose, initial phases
of treatment
Abbreviations- AP: antipsychotic; Adj: adjusted; CI: confidence intervals; HR: hazard ratio; OR: odds ratio; RR: risk ratio.
https://doi.org/10.1371/journal.pone.0187034.t002
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symptoms, others are potentially related to pneumonia. Further detail on the web of biological
functions related to PTAFR and TBAX2R are shown in the supplementary files (S7–S9 Figs).
Discussion
Drug safety is an important public health concern, as can be seen by the continuous efforts in
pharmacovigilance to identify, quantify and minimize drug-related risks. Over the years, anti-
psychotic safety has been investigated using both spontaneous reporting system databases as
well as electronic medical records or claims databases. Whenever possible, the plausibility of
associations between adverse drug events and drug use is strengthened by confirming the bio-
logical plausibility of such events, especially in case of “type A” adverse drug reaction which
are dose-dependent and are based on pharmacological properties of the drug mechanism of
action effects.
Of the 41 articles identified in the systematic literature review, only 30 hypothesized a phar-
macological mechanism that could explain the antipsychotic-associated risk of pneumonia.
Furthermore, only one of these studies was designed in such a way that could reasonably asso-
ciate pneumonia to specific antipsychotic sub-groups, and therefore to a group of antipsychot-
ics with closely related physicochemical properties (e.g., butyrophenones and phenothiazines
among conventional antipsychotics)[4].
Fig 2. The polypharmacology of 7 commonly studied antipsychotics in the context of pneumonia,
across 34 proteins for which experimentally known pKi values are available. The affinities for the
receptors TRXA2R and PTAFR concern predicted, not experimentally known, values; these are presented
here for comparison purposes. Abbreviations: HTR- serotonin receptors; ADR: adrenergic receptors; DRDs-
dopamine receptors; HRHs: histamine receptors; CHRs- muscarinic receptors; KCNH2: hERG transporter,
SLC6A3: dopamine transporter, SLC6A4: serotonin transporter; TBXA2R- thromboxane A2 receptor;
PTAFR- platelet activating factor receptor. Color coding reflects the experimentally known pKi values, yellow
being inactive (pKi = 4; Ki = 100 nM), red being highly active (pKi = 9; Ki = 1 nM), and grey meaning that no
data is available for that interaction.
https://doi.org/10.1371/journal.pone.0187034.g002
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The approach underlying currently hypothesized mechanisms is limited because it is based
on the traditional view of ‘systems pharmacology’, thus excluding a priori any“off-target”
receptors and focusing on commonly known pharmacological systems, such as cholinergic,
histaminergic, serotonergic and dopaminergic classes. As a result, other targets potentially
mediating events of interest are not captured. A case in point is the identification of two novel
receptor targets which were not identifiable based on the major pharmacologic systems.
The main clinical implications of the study findings primarily illustrate that antipsychotics
of both classes have plausible mechanisms leading to pneumonia and/or lead to signs/symp-
toms that increase the risk of pneumonia. As a result, all APs should be used with caution and
sparingly in persons at risk of pneumonia, especially the elderly. Indeed, the finding of similar
risk of pneumonia across classes in the literature review conducted is consistent with a recently
published systematic review and meta-analysis [44]. Nevertheless, the very diverse target bind-
ing among single APs, as highlighted by the analysis of experimentally-known AP target-
Fig 3. Clusters identified for investigation for TBXA2R. TBXA2R is shown in black, associated nodes are represented in blue, primary interactors
of TBXA2 are shown in red and secondary interactors are shown in grey. The nodes are linked through physical interactions (data obtained from
geneMania database). Abbreviations- ADRB1: Adrenoceptor Beta 1; ARRB2: Arrestin Beta 2; ADRB1: Arrestin Beta 1;AGTR1: Angiotensin II
Receptor Type 1; AGTR1: Angiotensin II Receptor Type 1; ADRB2: Adrenoceptor Beta 2; TBXA2R: Thromboxane A2 Receptor; AGTRAP:
Angiotensin II Receptor Associated Protein;BDKRB2: Bradykinin Receptor B2;CAV3:Caveolin 3; CDH15: Cadherin 15; CDH2:Cadherin 2;EDNRA:
Endothelin Receptor Type A;G3BP2: G3BP Stress Granule Assembly Factor 2; GNA11: G Protein Subunit Alpha 11;GNAI2: G Protein Subunit
Alpha I2;GNA12: G Protein Subunit Alpha 12;GNA13: G Protein Subunit Alpha 13;GNAQ: G Protein Subunit Alpha Q;GNAS: GNAS Complex Locus;
GPRASP1: G Protein-Coupled Receptor Associated Sorting Protein 1;GRK5: G Protein-Coupled Receptor Kinase 5;HTR2B: 5-Hydroxytryptamine
Receptor 2B;HRH2: Histamine Receptor H2; ITGB1BP1: Integrin Subunit Beta 1 Binding Protein 1; KCNMA1: Potassium Calcium-Activated
Channel Subfamily M Alpha 1;NME1-MNE2: NME/NM23 nucleoside diphosphate kinase 1;OPRD1:Opioid Receptor Delta 1;OPRK1: Opioid
Receptor Kappa 1;OPRM1: Opioid Receptor Mu 1;PRKCA: Protein Kinase C Alpha; RAF1: Raf-1 Proto-Oncogene, Serine/Threonine Kinase;
WDR36: WD Repeat Domain 36; YWHAZ: Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Zeta.
https://doi.org/10.1371/journal.pone.0187034.g003
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binding, suggests that grouping antipsychotics into broad groups such as ‘atypical’ and ‘con-
ventional’ may not be helpful or accurate. This method of classifying antipsychotics is based
on the point in time when antipsychotics were marketed, with the older APs being termed
conventional or first generation and newer ones being referred to as atypical or second genera-
tion. In vitro findings presented in this study confirm that such a classification is misleading,
particularly concerning atypical APs, because there is a significant pharmacological heteroge-
neity among individual APs. Equally prone to being misleading are proposed mechanisms of
action for pneumonia, or other adverse outcomes, that assumed all AP drugs to have the same
or similar pharmacological action. The literature review conducted contains several such
examples of mechanisms of action which related to all APs. Researchers should not be content
with evaluating the risk of an outcome but should question the reason why such events occur,
considering that biological feasibility is one of the key criteria for causality. The present study
Fig 4. Clusters identified for PTAFR. PTAFR is shown in black, associated nodes from Table 1 are represented in blue, primary interactors of
TBXA2R are shown in red and secondary interactors are shown in grey.The nodes are linked through physical interactions (red edges) and
pathway interactions (blue edges). The data was obtained from geneMania software. Abbreviations- ADORA1: Adenosine A1 Receptor;
ADRB1:Adrenoceptor Beta 1; CCK: Cholecystokinin; CDC42:Cell Division Cycle 42; CNR2:Cannabinoid Receptor 2;ENG:Endoglin;GHR:
Growth Hormone Receptor; GLP1R: Glucagon Like Peptide 1 Receptor;GNAI3:G Protein Subunit Alpha I3;GNLY:Granulysin; HDAC5: Histone
Deacetylase 5; IKBKB: Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta; IL13RA1: Interleukin 13 Receptor Subunit Alpha 1; LYN:LYN
Proto-Oncogene, Src Family Tyrosine Kinase; OXTR:Oxytocin Receptor;PTGDS: Prostaglandin D2 Synthase; PTAFR: platelet activating factor
receptor;PTGER3: Prostaglandin E Receptor 3;RELN:Reelin; RGS16: Regulator Of G-Protein Signaling 16; SLC40A1: Solute Carrier Family 40
Member 1; TACR1: Tachykinin Receptor 1.
https://doi.org/10.1371/journal.pone.0187034.g004
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suggests that off-target pharmacology can play an important role in substantiating known sig-
nals. The novel mechanisms concerning TBXA2R and PTAFR as potential mediators of pneu-
monia symptoms constitute an important finding of this study.
PTAFR has already been linked to an increased risk of pneumococcal disease in particular
by facilitating the adhesion of pneumococcal bacteria to endothelial cells in the respiratory
tract, according to a recently published narrative review on the link between PTAFR and pneu-
mococcal disease using in vitro and in vivodata[60]. Platelet-activating factor binds to PTAFR,
activating the enzyme GTPase, up-regulating phospholipase C, D and A2 pathways and acti-
vating protein kinase C as well as tyrosine kinases, leading to an overall increase in inflamma-
tory response[60]. TBXA2R appears to have been less extensively studied than PTAFR in the
context of pneumonia, but has nevertheless been implicated in bronchial hyper-responsiveness
Fig 5. Biological processes involved in AP-associated pneumonia related to TBXA2R (upper panel) and PTAFR (lower panel).
Abbreviation- TBXA2R: thromboxane A2 receptor; PTAFR:platelet activating factor receptor.
https://doi.org/10.1371/journal.pone.0187034.g005
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[61] as well as bronchial constriction [62] in animal models, both of which may be risk factors
for pneumonia. We hypothesize that the increased risk of pneumonia-like symptoms mediated
by PTAFR and TBXA2R may be exerted through the control of capillary permeability at the
alveolar level. Impaired control of permeability may increase the quantity of fluids in the alve-
oli, thus causing edema, a primary risk factor as well as symptom of pneumonia. In addition,
pathways involved with the gene/protein clusters identified in relation to pneumonia symp-
toms also have a role in maintaining the structure of blood vessels. Impairment of this function
may negatively impact circulatory system’s physical properties, leading to leaking of fluids in
the alveoli. Control of platelet and coagulation homeostasis may also play a role in the increase
of fluids within alveoli after TBXA2R and PTAFR activation. Future studies should aim to
quantify the affinity of APs and other drugs associated with a risk of pneumonia also to these
two receptors in vitro. From a clinical point of view, it is relevant to identify the drug receptor-
binding profiles related leading to a specific adverse effect, in this case, pneumonia, as this may
help prevent the concomitant use of drugs having a potentially synergistic or additive risk of
that adverse effect. Furthermore, future studies should focus more on the single drug safety
profile rather than grouping antipsychotic drugs by class, as this may help to identify high risk
drugs as well as high risk patient groups and better support individualized medicine.
This paper has several strengths. The literature review allowed us to screen published mate-
rial for hypothesized mechanisms underlying pneumonia and understand what importance is
given to this aspect of drug safety. In addition, the in silicoapproaches to drug safety substanti-
ation used in the present paper build on each other, first using off-target pharmacology to
identify relevant novel receptors associated with pneumonia and then using Cytoscape to con-
struct likely biological cascades connecting the novel receptors to pneumonia symptoms.
Indeed, similar approaches to better drug safety, such as “medication-wide association stud-
ies”[63] and systems pharmacology [64] have been proposed to augment the capacity of cur-
rently used pharmacovigilance systems. Findings from this study confirmed existing receptor
targets for AP drugs but also provided two novel off-targets that may lead to AP-associated
pneumonia, namely PTAFR and TBXA2R.
There are however some limitations that should be borne in mind. Some of the hypothe-
sized signal substantiation mechanisms suggested in the published literature were found to be
of limited value as they did not mention a specific drug but focused on an entire drug class
(conventional or atypical) or even on antipsychotics in general. This constituted a limitation in
the starting point of collecting hypotheses, as it is unlikely that such suggested mechanisms
underlying AP-associated pneumonia are completely reliable given the physicochemical differ-
ences between each drug. With regards to the safety predictions generated by CT-link and the
generation of molecular cascades with Cytoscape, there are at least two inherent limitations
associated with any approach relying on signals therein. On one hand, the experimentally
known in vitro affinity data for drugs may be incomplete [14], which can have an impact on
the list of proteins included in the target signatures linked to safety terms and thus, on the abil-
ity to identify protein targets likely to be responsible for the AP-associated pneumonia. Given
the data sources used to carry out this study, it was not possible to examine whether there are
some mechanisms that are more strongly associated with the occurrence of pneumonia than
others. Finally, this work focused on a set of seven antipsychotic drugs for which there is a con-
siderable amount of bibliographical information in the context of the risk of pneumonia [25–
29].Therefore, our results cannot be considered exhaustive with regards to the current portfo-
lio of over 50 antipsychotic medications but can certainly be taken as a reference from which
substantiation analyses of AP-associated pneumonia could be performed.
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Conclusion
The literature review identified several biological mechanisms that could lead to pneumonia
with AP use. In vitro pharmacology data confirmed receptor affinities identified in thelitera-
ture review. Two targets, thromboxane A2 receptor (TBXA2R) and plateletactivating factor
receptor (PTAFR) were found to be novel AP target receptorspotentially associated with pneu-
monia. Biological pathways constructed usingCytoscape identified plausible biological links
potentially leading to pneumoniadownstream of TBXA2R and PTAFR. Innovative approaches
for biologicalsubstantiation of drug-adverse event associations may strengthen evidence on
drugsafety profiles and help tailoring pharmacological therapies.
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